Findings

What do systematic reviews say?

4,410 questions · 8,901 findings · 1,091 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,687 · 19%GRADE not reported 1,469 · 16.5%Very low 1,969 · 22.1%Low 2,060 · 23.1%Moderate 1,302 · 14.6%High 414 · 4.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings – denosumab vs placebo

Adverse effects of treatment · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

BMD Z score (total hip/femoral neck) · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

BMD Z score (lumbar spine) · women with low bone mass and β‐thalassaemia

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings – strontium ranelate vs placebo

BMD Z score (wrist) · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Incidence of fractures · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Mobility · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Quality of life (back pain VAS score in cm) · women with low bone mass and β‐thalassaemia

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings – strontium ranelate vs placebo

Adverse effects of treatment · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Faster rotation vs slower rotation

Quality of sleep · Shift workers

1 finding from 1 review

Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers 2023 · Cochrane Headline outcomes only
no estimate extracted
282 participants
Low

Summary of findings table ‐ Faster rotation vs slower rotation

Sleep length off‐shift · Shift workers

1 finding from 1 review

Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers 2023 · Cochrane Headline outcomes only
no estimate extracted
282 participants
Very low

Summary of findings table ‐ Faster rotation vs slower rotation

Sleepiness during shifts · Shift workers

1 finding from 1 review

Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers 2023 · Cochrane Headline outcomes only
no estimate extracted
62 participants
Very low

Summary of findings table ‐ Faster rotation vs slower rotation

Secondary outcomes (number of staff; number of hours worked; overtime; staff costs) · Shift workers

The review found no eligible studies for this question.

1 finding from 1 review

Adapting shift work schedules for sleep quality, sleep duration, and sleepiness in shift workers 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

Clinical response · people with inflammatory bowel disease

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

Clinical relapse · people with inflammatory bowel disease

High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).

1 finding from 1 review

Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
RR 0.48 [0.23, 1.01]
1 study · 34 participants
Low

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

Quality of life · people with inflammatory bowel disease

1 finding from 1 review

Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 46 participants
Very low

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

Withdrawals due to adverse events · people with inflammatory bowel disease

It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).

1 finding from 1 review

Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
RR 0.89 [0.06, 13.08]
3 studies · 104 participants
Very low

CLACfast vs CLACslow

All‐cause in‐hospital mortality by 36 weeks' postmenstrual ageUnit: number of infants with event · preterm infants with respiratory dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Automated oxygen delivery for preterm infants with respiratory dysfunction 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CLACfast vs CLACslow

Severe ROPUnit: number of infants with event · preterm infants with respiratory dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Automated oxygen delivery for preterm infants with respiratory dysfunction 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CLACfast vs CLACslow

Neurodevelopmental outcomes · preterm infants with respiratory dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Automated oxygen delivery for preterm infants with respiratory dysfunction 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CLACfast vs CLACslow

Time in desired SpO2 rangeScale: 0% to 100% of time · preterm infants with respiratory dysfunction

1 finding from 1 review

Automated oxygen delivery for preterm infants with respiratory dysfunction 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low